[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-detail-35943":3,"doc-seo-35943":29},{"code":4,"msg":5,"data":6},0,"success",{"doc_id":7,"user_id":8,"nickname":9,"user_avatar":10,"doc_module":4,"category_id":11,"category_name":12,"doc_title":13,"doc_description":14,"doc_content":15,"file_id":16,"file_url":17,"file_type":18,"file_size":19,"view_count":4,"is_deleted":4,"is_public":20,"is_downloadable":20,"audit_status":20,"page_count":21,"language":22,"language_code":23,"site_id":24,"html_lang":23,"table_of_contents":25,"faqs":26,"seo_title":13,"seo_description":14,"update_tm":27,"read_time":28},35943,1649267921044,"Ava Thompson","https://us-avatar.wpscdn.com/avatar/1800007509477c92dfb?_k=1779183583414876462",8,"Research & Report","Alogliptin Metformin Synergy Ameliorates Diabetes Associated Bone Loss via DPP-4 Activity and OPG/RANKL Signaling","Type 2 diabetes mellitus disrupts bone remodeling and increases fracture risk, while many antidiabetic therapies provide limited skeletal protection. This study assessed whether alogliptin and metformin counter diabetes-associated bone loss and whether combined therapy shows synergy. Molecular docking examined OPG/RANK/RANKL regulators, UMR-106 cells used MTT and combination index analyses, and female Wistar rats received 8-week treatment after diet/streptozotocin induction.","","cbCairOACEUjODib","https://ap.wps.com/l/cbCairOACEUjODib","pdf",6802285,1,18,"English","en",105,"# Abstract\n## Therapeutic rationale and study design\n## In vitro synergy assessment\n## In vivo diabetes model and bone outcomes\n## Mechanistic findings and conclusions","[{\"question\":\"What bone-related mechanisms are targeted in the study?\",\"answer\":\"The study focuses on DPP-4 activity modulation and the OPG/RANKL signaling axis regulating osteoclast-driven bone remodeling.\"},{\"question\":\"How was drug synergy between alogliptin and metformin evaluated?\",\"answer\":\"Synergy was assessed in UMR-106 osteoblast-like cells using MTT assays and combination index (CI) analysis, with a reported strong synergistic effect at a 1:8 ratio.\"},{\"question\":\"What effects did the combination therapy show in diabetic rats?\",\"answer\":\"The combination improved glycemic control, reduced inflammatory cytokines (TNF-α, IL-6), decreased osteoclast-related markers (TRACP-5b, RANKL), restored OPG/RANKL balance, and preserved bone microarchitecture measured by micro-CT and confirmed by histology/immunohistochemistry.\"}]",1782766890,45,null]